Dilazep

This classification denotes an alpha-adrenergic agonist with the molecular formula C31H44N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8KLC2BD5Z, chemically known as tetrahydro-1h-1,4-diazepine-1,4(5h)-dipropanol 3,4,5-trimethoxybenzoate (diester) but generally known as dilazep, which bears US NIH Compound Identifier 3074. European Medicines Agency schedules Dilazep in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07144MIG. The term DILAZEP is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules dilazep in its Anatomical Therapeutic Chemical (ATC) Classification. DILAZEP is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dilazep under HS 29339990 and SITC 51577. As of Q4 2014, DILAZEP remains the US FDA Preferred Term for this commodity. Dilazep bears US NLM identifiers UMLS ID C0012367 and NCI Concept Code C65389. SMILES: O(CCCN1CCN(CCC1)CCCOC(=O)C1CC(OC)C(OC)C(OC)C1)C(=O)C1CC(OC)C(OC)C(OC)C1.